60P received Priority Review Designation from the USFDA for Tafenoquine (TQ) for prevention of malaria in adults. Learn More
Developing therapeutic innovations that can significantly improve and extend people’s lives.
In 2010, 60° Pharmaceuticals began its mission to build a better world by undertaking research and action focused on aiding in the prevention of tropical diseases.
Escalating malaria care
to people in need around
the world
Advancing therapies for the treatment and prevention of malaria.
Meeting the challenges of
the global dengue endemic
With no commercially available drugs or vaccines to effectively combat dengue, 60P is poised to enter this treatment arena.
For the investment community
We are committed to serving the best interests of our investors.
CAREERS
Our team is committed to creating innovative, potentially lifesaving medicines to significantly impact the quality of life for those affected by tropical diseases worldwide.
429,000
Deaths annually in endemic countries from malaria
125,000,000
Travelers to endemic regions per annum
390,000,000
Dengue infections per year
202-327-5422
1025 Connecticut Ave. NW, Suite 1000, Washington, DC 20036